TabletsClinical Overview
Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the evening with water, with or without food (10 mg for adults; 5 mg for children 6-12 years). Syrup: Measure with an oral measuring cup. Dose must be reduced to 5 mg in moderate renal impairment (CrCl 30-49 mL/min).
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Mild somnolence/drowsiness (occurs in ~10-14%), fatigue, dry mouth, pharyngitis, dizziness, headache. Rare/Severe: Severe hypersensitivity reactions, angioedema, and urinary retention.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
May cause drowsiness; caution while driving or operating machinery. Avoid alcohol and central nervous system depressants. Reduce dose by 50% in renal impairment (eliminated predominantly unchanged by the kidneys).
Over-The-Counter (OTC)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Montelukast Sodium 10mg + Levocetirizine 5mg Tablets
Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.
Levocetirizine Dihydrochloride Tablets 10mg
Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.
Montelukast 4mg + Levocetirizine 2.5mg Syrup
Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.
Levocetirizine Dihydrochloride 5mg + Montelukast 10mg + Ambroxol Hydrochloride (SR) 75mg Tablets
Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.